Skip to main content
Erschienen in:

15.03.2024 | Review

Atezolizumab and Bevacizumab Targeted-Therapy in Advanced Hepatocellular Carcinoma: A Systematic Review of Cost-effectiveness Analyses

verfasst von: Ghader Mohammadnezhad, Hadi Esmaily, Maryam Talebi, Matin Jafari

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Atezolizumab (ATZ) plus bevacizumab (BVC) co-administration is one of the newest systemic interventions in advanced hepatocellular carcinoma (AHCC). This treatment approach is more costly and effective than other therapeutic interventions, significantly improving AHCC survival and health-related quality of life.

Aim

This economic study aimed to systematically review all cost-effectiveness analyses of ATZ/BVC combination in AHCC.

Method

A comprehensive search in scientific databases was performed using a highly sensitive syntax to find all related economic evaluations. The target population was AHCC patients. The intervention was ATZ/BVC, which was compared with sorafenib, nivolumab, and other anticancer strategies. We included studies that reported quality-adjusted life-years (QALYs) and/or life-years, costs, and incremental cost-effectiveness ratio (ICER), and finally, the characteristics of included studies were categorized.

Results

Out of 315 identified records, 12 cost-effectiveness analyses were eligible for inclusion in the systematic review. Treatment costs were significantly higher with ATZ/BVC in all studies (from 61,397 to 253,687 USD/patient compared to sorafenib and nivolumab, respectively). Incremental QALYs/patient varied from 0.35 to 0.86 compared to sintilimab/BVC and sorafenib. Although ICERs for drugs varied widely, all were united in the lack of cost-effectiveness of the ATZ/BVC. The willingness-to-pay threshold in all studies was lower than the ICER, which indicated a reluctance to pay for this treatment strategy by the health systems.

Conclusion

The ATZ/BVC combination is an expensive targeted immunotherapy in AHCC. Significant discounts in ATZ and BVC prices are essential for this novel approach to be cost-effective and extensively used.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Su TH, Liao SH, Hong CM, Liu CJ, Tseng TC, Liu CH, et al. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. Journal of Gastroenterology and Hepatology (Australia). 2019;34(12):2179–86.CrossRef Su TH, Liao SH, Hong CM, Liu CJ, Tseng TC, Liu CH, et al. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. Journal of Gastroenterology and Hepatology (Australia). 2019;34(12):2179–86.CrossRef
2.
Zurück zum Zitat Popescu I. Hepatocellular carcinoma - new trends. Memo - Magazine of European Medical Oncology. 2010;3(3):113–8.CrossRef Popescu I. Hepatocellular carcinoma - new trends. Memo - Magazine of European Medical Oncology. 2010;3(3):113–8.CrossRef
4.
Zurück zum Zitat Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13(12):2140–51.CrossRefPubMedPubMedCentral Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13(12):2140–51.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Masuzaki R, Yoshida H, Tateishi R, Shiina S, Omata M. Hepatocellular carcinoma in viral hepatitis: improving standard therapy. Best Pract Res Clin Gastroenterol. 2008;22(6):1137–51.CrossRefPubMed Masuzaki R, Yoshida H, Tateishi R, Shiina S, Omata M. Hepatocellular carcinoma in viral hepatitis: improving standard therapy. Best Pract Res Clin Gastroenterol. 2008;22(6):1137–51.CrossRefPubMed
6.
Zurück zum Zitat Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Reports. 2019;1(1):17–29.CrossRefPubMedPubMedCentral Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Reports. 2019;1(1):17–29.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Zhou K, Fountzilas C. Outcomes and quality of life of systemic therapy in advanced hepatocellular carcinoma. Cancers 2019, Vol 11, Page 861. 2019;11(6):861. Zhou K, Fountzilas C. Outcomes and quality of life of systemic therapy in advanced hepatocellular carcinoma. Cancers 2019, Vol 11, Page 861. 2019;11(6):861.
8.
Zurück zum Zitat Chang PE, Ong WC, Lui HF, Tan CK. Epidemiology and prognosis of paraneoplastic syndromes in hepatocellular carcinoma. ISRN Oncol. 2013;11(2013):1–8. Chang PE, Ong WC, Lui HF, Tan CK. Epidemiology and prognosis of paraneoplastic syndromes in hepatocellular carcinoma. ISRN Oncol. 2013;11(2013):1–8.
9.
Zurück zum Zitat Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;1(72):28–36.CrossRef Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;1(72):28–36.CrossRef
10.
Zurück zum Zitat Saiyed M, Byrnes J, Srivastava T, Scuffham P, Downes M. Cost-effectiveness of lenvatinib compared with sorafenib for the first-line treatment of advanced hepatocellular carcinoma in Australia. Clin Drug Investig. 2020;40(12):1167–76.CrossRefPubMed Saiyed M, Byrnes J, Srivastava T, Scuffham P, Downes M. Cost-effectiveness of lenvatinib compared with sorafenib for the first-line treatment of advanced hepatocellular carcinoma in Australia. Clin Drug Investig. 2020;40(12):1167–76.CrossRefPubMed
11.
Zurück zum Zitat Yuen SC, Amaefule AQ, Kim HH, Owoo BV, Gorman EF, Mattingly TJ. A systematic review of cost-effectiveness analyses for hepatocellular carcinoma treatment. Pharmacoecon Open. 2021;24:1–11. Yuen SC, Amaefule AQ, Kim HH, Owoo BV, Gorman EF, Mattingly TJ. A systematic review of cost-effectiveness analyses for hepatocellular carcinoma treatment. Pharmacoecon Open. 2021;24:1–11.
12.
Zurück zum Zitat Kim JJ, McFarlane T, Tully S, Wong WWL. Lenvatinib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma: a cost–utility analysis. Oncologist. 2020;25(3):e512–9.CrossRefPubMed Kim JJ, McFarlane T, Tully S, Wong WWL. Lenvatinib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma: a cost–utility analysis. Oncologist. 2020;25(3):e512–9.CrossRefPubMed
13.
Zurück zum Zitat Sieg M, Hartmann M, Settmacher U, Arefian H. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States. BMC Gastroenterol. 2020;20(1). Sieg M, Hartmann M, Settmacher U, Arefian H. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States. BMC Gastroenterol. 2020;20(1).
14.
Zurück zum Zitat Sirohi B, Shrikhande S, Gaikwad V, Patel A, Patkar S, Goel M, et al. Indian Council of Medical Research consensus document on hepatocellular carcinoma. Indian J Med Res. 2020;152(5):468–74.CrossRefPubMedPubMedCentral Sirohi B, Shrikhande S, Gaikwad V, Patel A, Patkar S, Goel M, et al. Indian Council of Medical Research consensus document on hepatocellular carcinoma. Indian J Med Res. 2020;152(5):468–74.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Mohammadnezhad G, Noqani H, Rostamian P, Sattarpour M, Arabloo J. Lenvatinib in the treatment of unresectable hepatocellular carcinoma: a systematic review of economic evaluations. Eur J Clin Pharmacol [Internet]. 2023[cited 2023];79(7):885–95. Available from: https://link.springer.com/article/https://doi.org/10.1007/s00228-023-03502-7 Mohammadnezhad G, Noqani H, Rostamian P, Sattarpour M, Arabloo J. Lenvatinib in the treatment of unresectable hepatocellular carcinoma: a systematic review of economic evaluations. Eur J Clin Pharmacol [Internet]. 2023[cited 2023];79(7):885–95. Available from: https://​link.​springer.​com/​article/​https://​doi.​org/​10.​1007/​s00228-023-03502-7
16.
Zurück zum Zitat Dekervel J, Van Pelt J, Verslype C. Advanced unresectable hepatocellular carcinoma: New biologics as fresh ammunition or clues to disease understanding? Curr Opin Oncol. 2013;25(4):409–16.CrossRefPubMed Dekervel J, Van Pelt J, Verslype C. Advanced unresectable hepatocellular carcinoma: New biologics as fresh ammunition or clues to disease understanding? Curr Opin Oncol. 2013;25(4):409–16.CrossRefPubMed
17.
Zurück zum Zitat Giuliani J, Mantoan B, Bonetti A. The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma. J Oncol Pharm Pract. 2021;10781552211045012. Giuliani J, Mantoan B, Bonetti A. The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma. J Oncol Pharm Pract. 2021;10781552211045012.
18.
Zurück zum Zitat Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, PRISMA, et al. explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. The BMJ. 2020;2021:372. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, PRISMA, et al. explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. The BMJ. 2020;2021:372.
19.
Zurück zum Zitat CHEERS Checklist Items to include when reporting economic evaluations of health interventions. CHEERS Checklist Items to include when reporting economic evaluations of health interventions.
20.
Zurück zum Zitat Liu K, Zhu Y, Zhu H. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Immunol. 2023;11(13):8153. Liu K, Zhu Y, Zhu H. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Immunol. 2023;11(13):8153.
21.
Zurück zum Zitat Chiang CL, Chan SK, Lee SF, Choi HCW. First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis. Cancers (Basel). 2021;13(5). Chiang CL, Chan SK, Lee SF, Choi HCW. First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis. Cancers (Basel). 2021;13(5).
22.
Zurück zum Zitat Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2). Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2).
23.
Zurück zum Zitat Wen F, Zheng H, Zhang P, Liao W, Zhou K, Li Q. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis in China and the United states. Liver Int. 2021;41(5):1097–104.CrossRefPubMed Wen F, Zheng H, Zhang P, Liao W, Zhou K, Li Q. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis in China and the United states. Liver Int. 2021;41(5):1097–104.CrossRefPubMed
24.
Zurück zum Zitat Zhang X, Wang J, Shi J, Jia X, Dang S, Wang W. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma. JAMA Netw Open. 2021;4(4). Zhang X, Wang J, Shi J, Jia X, Dang S, Wang W. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma. JAMA Netw Open. 2021;4(4).
25.
Zurück zum Zitat Li L, Yang S, Chen Y, Tian L, He Y, Wu B, et al. Immune checkpoint inhibitors plus an anti-VEGF antibody as the first-line treatment for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Pharmacol. 2022;1:13. Li L, Yang S, Chen Y, Tian L, He Y, Wu B, et al. Immune checkpoint inhibitors plus an anti-VEGF antibody as the first-line treatment for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Pharmacol. 2022;1:13.
26.
Zurück zum Zitat Li Y, Liang X, Li H, Chen X. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer. 2022;128(22):3995–4003.CrossRefPubMed Li Y, Liang X, Li H, Chen X. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer. 2022;128(22):3995–4003.CrossRefPubMed
27.
Zurück zum Zitat Zhao M, Pan X, Yin Y, Hu H, Wei J, Bai Z, et al. Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis. Front Public Health. 2022;15(10):758. Zhao M, Pan X, Yin Y, Hu H, Wei J, Bai Z, et al. Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis. Front Public Health. 2022;15(10):758.
30.
Zurück zum Zitat Gong H, Ong SC, Li F, Weng Z, Zhao K, Jiang Z. Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China. Cost Effectiveness and Resource Allocation [Internet]. 2023 [cited 2023];21(1):1–12. Available from: https://resource-allocation.biomedcentral.com/articles/https://doi.org/10.1186/s12962-023-00435-x Gong H, Ong SC, Li F, Weng Z, Zhao K, Jiang Z. Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China. Cost Effectiveness and Resource Allocation [Internet]. 2023 [cited 2023];21(1):1–12. Available from: https://​resource-allocation.​biomedcentral.​com/​articles/​https://​doi.​org/​10.​1186/​s12962-023-00435-x
31.
Zurück zum Zitat Wang L, Peng Y, Qin S, Wan X, Zeng X, Li S, et al. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. PLoS One [Internet]. 2023 [cited 2023];18(4):e0279786. Available from: https://journals.plos.org/plosone/article?id=https://doi.org/10.1371/journal.pone.0279786 Wang L, Peng Y, Qin S, Wan X, Zeng X, Li S, et al. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. PLoS One [Internet]. 2023 [cited 2023];18(4):e0279786. Available from: https://​journals.​plos.​org/​plosone/​article?​id=​https://​doi.​org/​10.​1371/​journal.​pone.​0279786
32.
Zurück zum Zitat Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.CrossRefPubMed Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.CrossRefPubMed
33.
Zurück zum Zitat Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 2021;22(7):977–90.CrossRefPubMed Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 2021;22(7):977–90.CrossRefPubMed
34.
Zurück zum Zitat Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;1(30):v874–5.CrossRef Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;1(30):v874–5.CrossRef
35.
Zurück zum Zitat Zhang BH, Cai YS, Jiang L, Yang JY. Donafenib as a first-line monotherapy for advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2021;10(5):737.CrossRefPubMedPubMedCentral Zhang BH, Cai YS, Jiang L, Yang JY. Donafenib as a first-line monotherapy for advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2021;10(5):737.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, et al. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113.CrossRefPubMed Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, et al. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113.CrossRefPubMed
37.
Zurück zum Zitat Yousefi N, Salimi A, Mohammadnezhad G, Taheri S, Peiravian F. A cost-effectiveness analysis of adding cetuximab to the first-line treatment of metastatic colorectal carcinoma in Iran; considering genetic screening for precision medicine. J Gastrointest Cancer [Internet]. 2023 [cited 2023];1–8. Available from: https://link.springer.com/article/https://doi.org/10.1007/s12029-022-00904-1 Yousefi N, Salimi A, Mohammadnezhad G, Taheri S, Peiravian F. A cost-effectiveness analysis of adding cetuximab to the first-line treatment of metastatic colorectal carcinoma in Iran; considering genetic screening for precision medicine. J Gastrointest Cancer [Internet]. 2023 [cited 2023];1–8. Available from: https://​link.​springer.​com/​article/​https://​doi.​org/​10.​1007/​s12029-022-00904-1
38.
Zurück zum Zitat Mohammadnezhad G, Sattarpour M, Moradi N. Budget impact analysis of breast cancer medications: a systematic review. J Pharm Policy Pract [Internet]. 2022 [cited 2023];15(1):1–14. Available from: https://link.springer.com/articles/https://doi.org/10.1186/s40545-022-00493-1 Mohammadnezhad G, Sattarpour M, Moradi N. Budget impact analysis of breast cancer medications: a systematic review. J Pharm Policy Pract [Internet]. 2022 [cited 2023];15(1):1–14. Available from: https://​link.​springer.​com/​articles/​https://​doi.​org/​10.​1186/​s40545-022-00493-1
39.
Zurück zum Zitat Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.CrossRefPubMed Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.CrossRefPubMed
40.
Zurück zum Zitat Oechsle K, Ullrich A, Marx G, Benze G, Wowretzko F, Zhang Y, et al. Prevalence and predictors of distress, anxiety, depression, and quality of life in bereaved family caregivers of patients with advanced cancer. https://doi.org/10.1177/1049909119872755. 2019;37(3):201–13. Oechsle K, Ullrich A, Marx G, Benze G, Wowretzko F, Zhang Y, et al. Prevalence and predictors of distress, anxiety, depression, and quality of life in bereaved family caregivers of patients with advanced cancer. https://​doi.​org/​10.​1177/​1049909119872755​. 2019;37(3):201–13.
Metadaten
Titel
Atezolizumab and Bevacizumab Targeted-Therapy in Advanced Hepatocellular Carcinoma: A Systematic Review of Cost-effectiveness Analyses
verfasst von
Ghader Mohammadnezhad
Hadi Esmaily
Maryam Talebi
Matin Jafari
Publikationsdatum
15.03.2024
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 2/2024
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-024-01038-2

Neu im Fachgebiet Onkologie

Metastasiertes CRC: besser Checkpointhemmer im Doppelpack!

Die Kombination von Nivolumab plus Ipilimumab ist beim metastasierten Kolorektalkarzinom mit MSI-H- oder dMMR klar im Vorteil gegenüber einer Nivolumab-Monotherapie: Das Progressionsrisiko war damit in einer Phase-3-Studie um 38% reduziert.

Große Trinkmengen bei Blasentumoren möglicherweise von Nachteil

Beim nicht-muskelinvasiven Blasenkrebs scheint eine hohe Flüssigkeitszufuhr keinen schützenden Effekt in Bezug auf das Risiko eines Rezidivs oder einer Krankheitsprogression zu haben. Eine niederländische Studie legt sogar nahe, dass große Trinkmengen das Fortschreiten der Erkrankung begünstigen könnten.

Höhere Trefferquoten bei Brustkrebsscreening dank KI?

Künstliche Intelligenz unterstützt bei der Auswertung von Mammografie-Screenings und senkt somit den Arbeitsaufwand für Radiologen. Wie wirken sich diese Technologien auf die Trefferquote und die Falsch-positiv-Rate aus? Das hat jetzt eine Studie aus Schweden untersucht.

Urintest auf Prostatakrebs funktioniert mit Erststrahlurin

Ein auf die Expression von 18 Genen gestützter Urintest auf klinisch signifikanten Prostatakrebs könnte offenbar auch in Anwendung auf Erststrahlurin dazu dienen, unnötige Biopsien zu vermeiden.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.